Clinical study of ADG106 in combination with other therapies in advanced solid tumors and hematological malignancies
Latest Information Update: 24 May 2021
At a glance
- Drugs ADG 106 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 24 May 2021 New trial record
- 19 May 2021 According to an Adagene media release, preparations are underway to initiate this study.
- 31 Mar 2021 According to an Adagene media release, Phase 1b read-out from Australia trial in combination therapy in 2H21